FDA expands Avastin label

FDA approved a label expansion for Avastin bevacizumab from Genentech Inc. to include second-line treatment in combination with an irinotecan- or oxaliplatin-based chemotherapy regimen in patients with metastatic colorectal cancer (mCRC) who have progressed after first-line treatment with Avastin. The Roche (SIX:ROG; OTCQX:RHHBY) unit said the new indication will allow mCRC patients who receive first-line treatment with Avastin to continue to receive the humanized mAb against VEGF with a different chemotherapy regimen after their cancer worsens. Avastin is already approved for the indication in the EU. ...